These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 10484067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.
    Joe AK, Liu H, Xiao D, Soh JW, Pinto JT, Beer DG, Piazza GA, Thompson WJ, Weinstein IB.
    J Exp Ther Oncol; 2003; 3(2):83-94. PubMed ID: 12822514
    [Abstract] [Full Text] [Related]

  • 3. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT, Piazza GA, Pamukcu R, Thompson WJ, Weinstein IB.
    Clin Cancer Res; 2003 Oct 15; 9(13):4972-82. PubMed ID: 14581372
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q, Luo X, Huang Y, Sheikh MS.
    Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.
    Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA.
    Urology; 1999 Feb 05; 53(2):440-5. PubMed ID: 9933075
    [Abstract] [Full Text] [Related]

  • 16. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.
    Huang Y, He Q, Hillman MJ, Rong R, Sheikh MS.
    Cancer Res; 2001 Sep 15; 61(18):6918-24. PubMed ID: 11559570
    [Abstract] [Full Text] [Related]

  • 17. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
    Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN.
    Neoplasia; 1999 Jun 15; 1(2):170-6. PubMed ID: 10933052
    [Abstract] [Full Text] [Related]

  • 18. Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
    Ma L, Xie YL, Yu Y, Zhang QN.
    World J Gastroenterol; 2005 Mar 28; 11(12):1829-32. PubMed ID: 15793875
    [Abstract] [Full Text] [Related]

  • 19. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C, Narayanan NK.
    Clin Cancer Res; 2007 Oct 01; 13(19):5965-73. PubMed ID: 17908994
    [Abstract] [Full Text] [Related]

  • 20. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
    Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC.
    Cancer Prev Res (Phila); 2009 Jun 01; 2(6):572-80. PubMed ID: 19470791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.